

The relative responsiveness to inhaled leukotriene E₄, methacholine and histamine in normal and asthmatic subjects

S.P. O'Hickey**, J.P. Arm* **, P.J. Rees**, B.W. Spur*, T.H. Lee* **

The relative responsiveness to inhaled leukotriene E₄, methacholine and histamine in normal and asthmatic subjects. S.P. O'Hickey, J.P. Arm, P.J. Rees, B.W. Spur, T.H. Lee.

ABSTRACT: The relative bronchoconstricting potencies of leukotriene E₄ (LTE₄), methacholine and histamine have been compared in asthmatic and normal subjects. LTE₄ responsiveness in asthmatic subjects, as measured by the dose which produced a 35% fall in specific airways conductance (PD₃₅), ranged from 0.06–24.4 nmol (geom mean 4.1 nmol, n=20). This was significantly less than the PD₃₅ in normal subjects (range 39.0–370 nmol, geom mean 105 nmol, n=6; p<0.001). There was a correlation between LTE₄ and methacholine responsiveness (r=0.84, p<0.001) and between LTE₄ and histamine responsiveness (r=0.79, p<0.001). LTE₄ was 73 times more potent than methacholine and 112 times more potent than histamine in asthmatic subjects. LTE₄ was 20 times more potent than methacholine and 58 times more potent than histamine in normal subjects. LTE₄ is a potent bronchoconstrictor agent, and LTE₄ responsiveness correlates with both histamine and methacholine responsiveness.
Eur Respir J, 1988, 1, 913–917.

Departments of *Medicine and **Respiratory Medicine, United Medical and Dental Schools, Guy's Hospital, London SE1 9RT, U.K.

Correspondence: Dr. T.H. Lee, Dept of Medicine, Guy's Hospital, London SE1 9RT, UK.

Keywords: Asthma, histamine, leukotriene, methacholine, responsiveness.

Received: February, 1988; accepted after revision: August 23, 1988.

This work was supported in part by the Asthma Research Council, UK.

Enhanced airway responsiveness to a wide range of stimuli is the hallmark of bronchial asthma [1]. Bronchoconstrictor agonists which include histamine [2], methacholine [3], prostaglandin (PG) F_{2α} [4] and PGD₂ [5] and physical stimuli such as exercise [6], and cold air hyperventilation [7] are more potent in constricting the airways of asthmatic subjects than those of normal individuals.

The sulphidopeptide leukotrienes (LT) C₄, LTD₄ and LTE₄ comprise the activity previously recognized as slow-reacting substance of anaphylaxis (SRS-A) [8]. In humans the leukotrienes are potent bronchoconstrictors when inhaled and airways responsiveness to LTC₄ and LTD₄ correlates with that to histamine and methacholine [9, 10]. There has only been one report in humans on the *in vivo* effects of LTE₄, the most stable of the sulphidopeptide leukotrienes. Davidson *et al.* [11] compared the airways response of six asthmatic and five normal subjects to inhaled LTE₄ and histamine, by measuring airways response in terms of both forced expiratory volume in one second (FEV₁) and flow at 30% of vital capacity above the residual volume (V̇30).

There is very limited data on the relationship of LTE₄ responsiveness with other indices of non-specific airways responsiveness. We have therefore measured the airways responsiveness to LTE₄ in normal and asthmatic subjects and compared this with histamine and methacholine responsiveness.

Patients and methods

Twenty asthmatic subjects (8 males and 12 females) aged between 15 and 43 yrs (mean 27 yrs) were studied together with six normal subjects (4 males and 2 females) aged 23 to 36 yrs (mean 30 yrs). Asthmatic subjects were selected at random from patients attending the asthma clinic and normal subjects from volunteers working in the laboratory. Sixteen of the asthmatic subjects and two normal subjects were atopic. Baseline specific airways conductance (sGaw) of the asthmatic subjects ranged from 0.9–2.75 s⁻¹·kPa⁻¹ and from 1.8–5.7 s⁻¹·kPa⁻¹ for normal subjects. Fourteen asthmatic subjects were taking regular inhaled beclomethasone dipropionate and all asthmatic individuals were using inhaled beta₂-agonists as required. No subject was using theophylline or had taken oral corticosteroids or inhaled cromolyn for at least one month prior to the study. Medication was withheld for at least 8 h before each challenge and challenges were performed for each individual at the same time each day. The study was approved by the Guy's Hospital Ethical Committee and each subject gave informed consent.

Study design

All subjects attended the laboratory on two occasions at least two weeks apart. Subjects were challenged with

LTE₄ or with methacholine in random order. Nine asthmatic subjects and all normal subjects attended the laboratory on one more occasion and were challenged with histamine. The remaining eleven subjects declined a further bronchial challenge.

Histamine and methacholine challenges

Inhalation challenges were performed as previously described using a Hudson nebulizer linked to a breath activated dosimeter [12]. Delivery of air to the nebulizer was regulated to a pressure of 138 kPa (20 pounds per square inch), for a duration of 0.6 s from the start of inspiration of each breath. Under these conditions the Hudson nebulizer delivers droplets with a mass median aerodynamic diameter of 1.6 µm and the output of the nebulizer is 2.6 µl per breath. Following baseline measurements of sGaw the subjects inhaled 5 breaths of phosphate buffered saline (PBS) as a control. Each inhalation started at functional residual capacity and terminated at approximately 70% of baseline vital capacity; a 5 s breath hold was maintained at the end of each inhalation. If the decrease in sGaw was <10% the patients were subjected to histamine or methacholine challenge.

Two-fold increasing concentrations of histamine acid phosphate or methacholine chloride (Sigma, Poole, Dorset) diluted in PBS were inhaled from a concentration of 0.5 mg·ml⁻¹ (1.6 mM and 2.6 mM, respectively) to 1.6 mg·ml⁻¹ (54.2 mM and 83.2 mM, respectively) for asthmatic subjects and 2.0 mg·ml⁻¹ (6.5 mM and 10.2 mM, respectively) to 6.4 mg·ml⁻¹ (208 mM and 324 mM, respectively) for normal subjects. Specific airways conductance (sGaw) was measured 2 min after each inhalation and increasing concentrations were administered until sGaw had fallen by more than 35%. The coefficient of variation for histamine and methacholine challenges has previously been shown to be 15% in this laboratory [13]. Asthmatic subjects bronchoconstrict at concentrations of less than 0.8 mg·ml⁻¹.

LTE₄ inhalation challenges

LTE₄ was prepared by total chemical synthesis as described previously [14] and frozen under argon at -70°C. LTE₄ was analysed before inhalation challenge by reverse phase high performance liquid chromatography (RP-HPLC) on a 10 micron C₁₈ ultrasil-ODS column (4.6 250 mm; Beckman Instruments Inc, Berkeley, CA)

Table 1. - The doses of LTE₄ and methacholine and histamine which produced a 35% fall in sGaw (PD₃₅) in normal and asthmatic subjects

Subjects	PD ₃₅ LTE ₄	PD ₃₅ Methacholine	PD ₃₅ Histamine	Relative Potency LTE ₄ /Methacholine	Relative Potency LTE ₄ /Histamine
asthmatic	nmol	µmol	µmol		
1	2.90	0.76	0.9	261	309
2	16.00	0.70	0.7	44	45
3	4.00	0.51	2.2	127	550
4	7.00	0.26	2.6	36	371
5	5.20	0.23	0.3	44	51
6	9.00	0.32	0.4	36	45
7	19.00	0.90	3.0	47	158
8	4.40	0.26		58	
9	12.20	0.12		9	
10	6.10	0.94		154	
11	1.20	0.11		92	
12	17.80	0.25		14	
13	2.90	0.28		97	
14	6.20	0.90		145	
15	6.00	0.47	0.5	78	90
16	24.40	0.80	0.8	33	33
17	0.06	0.01		241	
18	7.20	1.90		263	
19	0.75	0.07		93	
20	0.28	0.05		178	
geometric mean	4.10	0.30	0.09	73	112
normal					
1	172.0	0.8	8.0	4.4	46
2	370.0	4.1	39.0	11.0	105
3	90.0	1.1	3.2	12.2	36
4	56.6	3.3	4.4	59.2	78
5	39.0	1.4	4.2	35.1	107
6	115.0	6.2	3.2	53.9	28
geometric mean	105.9	2.1	6.2	20.0	58

at a flow rate of 1 ml·min⁻¹ with 65% methanol (BDH), 34.9% water, 0.1% acetic acid, pH 5.6, as solvent. Absorbance was monitored with an on-line spectrophotometer linked to an integrator (Spectraphysics, model SP 4270). The purity of LTE₄ before challenge was confirmed by its elution as a single peak at its unique retention time of 25±0.4 min (mean±SEM, n=10) in this solvent system. The concentration of the stock solution was assessed by UV scanning at 280 nm assuming an extinction coefficient of 40,000 cm⁻¹·M⁻¹ and dilutions of LTE₄ were prepared in PBS. On four occasions samples of the solution remaining in the nebulizer after the highest concentration of LTE₄ was administered were analysed by RP-HPLC and by measurement of ultraviolet absorbance at 280 nm to determine if the purity or concentration of LTE₄ had changed during nebulization. LTE₄ after nebulization eluted as a single peak when subjected to RP-HPLC and the concentration differed by less than 10% from pre-nebulization values.

For LTE₄ challenges, each subject inhaled geometrically increasing concentrations of LTE₄ starting at a concentration of 0.18 µg·ml⁻¹ (0.4 µM) in asthmatic subjects and 4.6 µg·ml⁻¹ (10 µM) in normal subjects as determined from previous studies [11]. sGaw was measured every 5 min for 15 minutes. If a 35% decrease in sGaw was not achieved within 15 minutes the concentration of LTE₄ in the nebulizer was increased by 3-fold and the protocol repeated. The timings of observations were based on the results of previous studies [11]. Bronchoconstriction commences at 5 minutes after inhalation of LTE₄ with maximal bronchoconstriction occurring at between 10–15 minutes after inhalation.

Measurements of sGaw were made in a total body plethysmograph linked to a digital computer as previously described [15]. Four to six measurements of sGaw were recorded at each time point and the mean value was calculated. Baseline sGaw was >0.9 s⁻¹·kPa⁻¹ prior to each challenge in asthmatic subjects. Mean baseline sGaw measurements did not differ significantly in the asthmatic subjects on the three study days, being 1.49±0.09 s⁻¹·kPa⁻¹, 1.52±0.09 s⁻¹·kPa⁻¹, and 1.44±0.09 s⁻¹·kPa⁻¹ prior to methacholine, LTE₄ and histamine challenges, respectively.

Analysis of data

The cumulative dose of histamine or methacholine required to produce a 35% fall in sGaw (PD₃₅) was determined by linear interpolation from the log dose-response curve. Log transformed data was analysed by Student's t-test and correlations were assessed by the linear regression analysis.

Results

Relative potencies of LTE₄, methacholine and histamine asthmatic subjects. The LTE₄ PD₃₅ sGaw in asthmatic subjects ranged from 0.06–24.4 nmol (geom mean 4.1 nmol, n=20), the methacholine PD₃₅ sGaw ranged from 0.01–1.9 µmol (geom mean 0.30 µmol, n=20), and the

histamine PD₃₅ sGaw ranged from 0.3–3.0 µmol (mean 0.9 µmol, n=9) (table 1). The relative potency of LTE₄ to methacholine (PD₃₅ Meth/PD₃₅ LTE₄) ranged from 9–263 (geom mean 73, n=20). The relative potency of LTE₄ to histamine (PD₃₅ His/PD₃₅ LTE₄) ranged from 45–550 (geom mean 112, n=9).

Normal subjects. The LTE₄ PD₃₅ sGaw in normal subjects ranged from 39–370 nmol (geom mean 105.9 nmol, n=6) (table 1), the methacholine PD₃₅ sGaw ranged from 0.8–6.2 µmol (geom mean 2.1 µmol, n=6), and the histamine PD₃₅ sGaw in ranged from 3.2–39 µmol (geom mean 6.2 µmol, n=6). The airways responsiveness to LTE₄, methacholine and histamine was significantly greater in asthmatic than in normal subjects (p<0.001) (tables 1 and 2). The relative potency of LTE₄ to methacholine in normal subjects ranged from 4.4–59.2 (geom mean 20, n=6). The relative potency of histamine to LTE₄ in normal subjects ranged from 28 to 107 (geom mean 58, n=6). Asthmatic subjects were 26 times more sensitive to LTE₄ than normal subjects whereas they were 7 times more sensitive to methacholine and histamine.

Correlation of airways responsiveness to LTE₄ with that to methacholine and histamine

There was a positive correlation between LTE₄ PD₃₅ and methacholine PD₃₅ (r=0.84, p<0.001, n=26) (fig. 1) and between LTE₄ PD₃₅ and histamine PD₃₅ (r=0.79, p<0.001, n=15) when linear regression was calculated for both asthmatic and normal subjects (fig. 2).




Fig. 1. — The correlation between LTE₄ PD₃₅ and methacholine PD₃₅. ● asthmatic subjects; ○ normal subjects.




Fig. 2. — The correlation between LTE₄ PD₃₅ and histamine PD₃₅. ● asthmatic subjects; ○ normal subjects.

Discussion

The airways responsiveness to LTE₄ has been compared to that of histamine and methacholine in normal and asthmatic subjects. Airways responsiveness to the bronchoconstrictor agents was assessed by constructing cumulative dose-response curves and the dose which produced a 35% decrease in specific airways conductance (PD₃₅) was obtained from the straight-line portion of the log dose-response curve by linear interpolation. The potencies of each agent were studied by comparison of the PD₃₅ values.

LTE₄ enhances bronchial hyperresponsiveness in asthmatic subjects [13], there is bioconversion of LTC₄ and LTD₄ to LTE₄ during a contractile reaction [16] and LTE₄ may persist at the site of release for a prolonged period of time [17]. Since there is bioconversion of LTC₄ and LTD₄ to LTE₄, it is likely that LTE₄ will contribute significantly to airflow obstruction at the site of release of the sulphidopeptide leukotrienes. Our data demonstrates that LTE₄ is a potent bronchoconstrictor agent in normal and asthmatic subjects and confirms the work of DAVIDSON *et al.* [11]. Using sGaw as the index of airway calibre, we found that LTE₄ was on average 20-fold and 73-fold more potent than methacholine and 58-fold and 112-fold more potent than histamine on a molar basis in normal and asthmatic subjects respectively. In addition, asthmatic subjects were approximately 25-fold more sensitive to LTE₄ than were normal subjects, but were only 7-fold more sensitive to histamine and methacholine.

We demonstrate for the first time that there is a positive correlation between LTE₄ PD₃₅ and histamine and methacholine PD₃₅ when both asthmatic and normal subjects are considered when the linear regression was

calculated for both of these subjects. Comparisons of results in the literature are complicated by differences in the aerosol delivery technique and the details of the airway measurements made. One approach to compare data from different studies is to evaluate the responsiveness of groups of normal and asthmatic subjects studied by the same investigators in terms of their relative responsiveness to leukotrienes and to reference agonists [18] ([normals/asthmatics] responsiveness to reference agonist divided by [normals/asthmatics] responsiveness to a leukotriene). The relative responsiveness of normal individuals for the reference agonist, histamine or methacholine, is greater than the relative responsiveness to leukotrienes in three of the four published studies [9, 10, 19, 20]. That is, in three of the four studies, asthmatic subjects failed to exhibit the same degree of hyperresponsiveness to a leukotriene than to the reference agonist. In these studies airway response was determined by measurement of FEV₁, and flow rates at 30% and 40% of forced vital capacity. Using sGaw as a measurement of large airways calibre [21, 22], we have demonstrated airway hyperresponsiveness to LTE₄ in asthmatic subjects. Our results are in agreement with those of SMITH *et al.* [9] in that the relative responsiveness to the leukotrienes in asthmatic subjects was 2- and 3-fold greater than that to histamine and methacholine, respectively, when airway calibre was determined by sGaw. These findings are consistent with the data of DAVIDSON *et al.* [11] and suggest that in bronchial asthma there may be site selectivity for leukotriene hyperresponsiveness, as compared to histamine and methacholine responsiveness, and that asthmatic subjects may be more hyperresponsive to the leukotrienes in the large airways.

References

- Hargreave FE, Ryan G, Thomson NC *et al.* — Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. *J Allergy Clin Immunol*, 1981, 68, 347–355.
- Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. — Bronchial reactivity to inhaled histamine: a method and clinical survey. *Clin Allergy*, 1977, 7, 235–243.
- Juniper EF, Frith PA, Hargreave FE. — Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. *Thorax*, 1981, 36, 575–579.
- Mathe AA, Hedqvist P, Holgren A, Svanborg N. — Bronchial reactivity to prostaglandin F₂ and histamine in patients with asthma. *Br Med J*, 1973, 1, 193–196.
- Hardy CC, Robinson C, Tattersfield AE, Holgate ST. — The bronchoconstrictor effect of inhaled prostaglandin D₂ in normal and asthmatic men. *N Engl J Med*, 1984, 311, 209–213.
- Anderton RC, Cuff MT, Frith PA *et al.* — Bronchial responsiveness to inhaled histamine and exercise. *J Allergy Clin Immunol*, 1979, 63, 315–320.
- Heaton RW, Henderson AF, Costello JF. — Cold air as a bronchial provocation technique: reproducibility and comparison with histamine and methacholine inhalation. *Chest*, 1984, 86, 810–814.
- Samuelsson B. — Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. *Science*, 1983, 220, 568–575.

9. Smith LJ, Greenberger PA, Patterson R, Krell RD, Bernstein PR. – The effect of inhaled leukotriene D₄ in humans. *Am Rev Respir Dis*, 1985, 131, 368–372.
10. Adelroth E, Morris MM, Hargreave FE, O'Byrne PM. – Airway responsiveness to leukotrienes C₄ and D₄ and to methacholine in patients with asthma and normal controls. *N Engl J Med*, 1986, 315, 480–484.
11. Davidson AB, Lee TH, Scanlon PD *et al.* – Bronchoconstrictor effects of leukotriene E₄ in normal and asthmatic subjects. *Am Rev Respir Dis*, 1987, 135, 333–337.
12. Eiser NM, Mills J, McRae KD, Snashall PD, Guz A. – Histamine receptors in normal human bronchi. *Clin Sci*, 1980, 58, 537–544.
13. Arm JP, Spur BW, Lee TH. – The effects of inhaled leukotriene E₄ on the airway responsiveness to histamine in asthmatic and normal subjects. *J Allergy Clin Immunol*, (In press).
14. Lewis RA, Drazen JM, Austen KF, Clarke DA, Corey EJ. – Identification of the C(6)-S conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. *Biochem Biophys Res Commun*, 1980, 96, 271–277.
15. Chowienczyk PJ, Rees PJ, Payne J, Clark TJH. – A new method for computer-assisted determination of airways resistance. *J Appl Physiol*, 1981, 50, 672–678.
16. Krillis S, Lewis RA, Corey EJ, Austen KF. – Bioconversion of C₆ sulfidopeptide leukotrienes by the responding guinea pig ileum determines the time course of its contraction. *J Clin Invest*, 1983, 71, 909–915.
17. Sautehin L, Vigarò T, Grassi E *et al.* – Release of leukotrienes induced by the Ca²⁺ ionophore A23187, from human lung parenchyma in vitro. *J Pharmacol Exp Ther*, 1985, 234, 217–221.
18. Drazen JA, Austen KF. – Leukotrienes and airway responses. *Am Rev Respir Dis*, 1987, 136, 985–998.
19. Griffin M, Weiss JW, Leitch AG *et al.* – Effects of leukotriene D on the airways in asthma. *N Engl J Med*, 1983, 308, 436–439.
20. Bisgaard H, Groth S, Masden F. – Bronchial hyperreactivity to leukotriene D₄ in exogenous asthma. *Br Med J*, 1985, 290, 1468–1471.
21. Macklem PT, Mead J. – Resistance of central and peripheral airways measured by retrograde catheter. *J Appl Physiol*, 1967, 22, 395–401.
22. Macklem PT, Wilson NJ. – Measurement of intrabronchial pressure in man. *J Appl Physiol*, 1965, 20, 653–663.

Réactivité comparée à l'inhalation de leukotriène E₄, de la métacholine et d'histamine, chez des sujets normaux et asthmatiques. S. P. O'Hickey, J. P. Arm, P. J. Rees, B. W. Spur, T. H. Lee.

RÉSUMÉ: La puissance bronchoconstrictrice relative de LTE₄, de la métacholine et de l'histamine a été comparée chez des sujets asthmatiques et normaux. La réactivité des asthmatiques à l'égard de LTE₄, exprimée par la dose qui produit une chute de 35% de la conductance spécifique des voies aériennes (PD₃₅), varie entre 0.06 et 24.4 nmol (moyenne géométrique: 4.1 nmol, n=20). Cette valeur est significativement plus faible que la PD₃₅ des sujets normaux (extrêmes: 39.0 à 370 nmol, moyenne géométrique: 105 nmol, n=6, p<0.001). L'on a observé une corrélation entre la réactivité à LTE₄ et la réactivité à la métacholine (r=0.84, p<0.001) ainsi qu'entre les réactivités à LTE₄ et à l'histamine (r=0.79, p<0.001). LTE₄ s'est avérée 73 fois plus puissante que la métacholine, et 112 fois plus puissante que l'histamine chez les sujets asthmatiques. Chez les sujets normaux, LTE₄ est 20 fois plus puissante que la métacholine et 58 fois plus puissante que l'histamine. LTE₄ est donc un agent bronchoconstricteur puissant, et la réactivité à LTE₄ est en corrélation à la fois avec celle à l'égard de l'histamine et à l'égard de la métacholine. *Eur Respir J.*, 1988, 1, 913–917.